Platform

Modern clinical trials employ various digital-based tools and technologies designed to increase the speed, accuracy, and ease of conducting clinical trials. In the best-case scenario, these tools are housed in the same experience or a  “clinical trial platform.” 

Clinical trial platforms are software-based, web-based, and/or cloud-based solutions that facilitate clinical trial research throughout its entire lifecycle. They offer a complete technology ecosystem that connects patients, research sites, and trial sponsors from patient recruitment to close out and data submission. Users of clinical trial platforms can access and operationalize all of their digital-based tools through this connected platform. Platforms can prevent users from accessing parts of the platform not permitted for them. For instance, participants can not view other participants' data or gain access to tools meant for sites. Other users, like sponsors’ study teams, have access to the full suite of tools as needed based on their roles.

The next level of clinical trial data capture is here. Gone are the days of paper, illegible handwriting, and data quality nightmares. eCOA, or electronic Clinical Outcome Assessments, and ePRO, or electronic Patient-Reported Outcomes, are revolutionizing the way clinical trials generate data. Both leverage digital tools to collect information electronically, offering a treasure trove of benefits. eCOA acts as the umbrella term, encompassing data from various sources like patients (ePRO), clinicians, observers, and even performance-based assessments. This holistic approach paints a more complete picture of a patient's experience. ePRO, as a subset, shines the spotlight directly on the patient's voice, capturing their symptoms, quality of life, and other critical self-reported measures.

Hear from industry leaders at this unique virtual event showcasing the eCOA/ePRO solutions of partners who are ready to help you with your clinical trial data capture needs.  Early registration is open via the form to your right.  

A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study in the highly competitive weight loss market. Their primary goal was toreduce the client’s average study build timelines from 16-20 weeks, down to just 8 weeks,a reduction of more than 50%.

‍

See how Medable was able to meet the customer's goal with this case study.

According to Grandview Research,the hybrid and decentralized clinicaltrial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct.

Over the last four days, the DIA 2023 conference has Illuminated downtown Boston as thousands of “industry, regulatory, government, academics, and patients” come together to  “problem-solve, and discuss global and local challenges facing the life sciences community.”

Much like JP Morgan week and SCOPE before it, what happens at DIA often makes waves across our industry, helping set the tone for our future.

Thus, we’re providing some of the biggest and brightest takeaways from this week’s conference below. 

‍

Understand the benefits of web-enabled research tools and how they work.

‍

‍

Combining multiple market solutions at the site level can result in a negative experience due to different processes, login credentials, and redundant training. A unified DCT platform that works seamlessly with other core clinical systems to streamline workflows and simplify key trial processes.

‍